CSCGP-Gilda's Club presents Dr. Janos Tanyi, U of P Abramson's Cancer Center on Immunotherapy

PENN MEDICINES CANCER VACCINE: The Future of Cancer Treatment
About this Event: Dr. Janos Tanyi from the University of Pennsylvania Abramsons Cancer Center Will Explain How a Vaccine Made from a Patients Own Tumor Boosts the Immune System to Kill Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer. On Thursday, December 5th at 6:30 pm Dr. Janos Tanyi, MD, PhD, Surgeon and Assistant Professor of Obstetrics and Gynecology at the University of Pennsylvania Abramsons Cancer Centers Perelman Center for Advanced Medicine and Principal Investigator will be at Gildas Club Delaware Valley. Dr. Tanyi will explain to cancer patients and survivors as well as health care practitioners how Penn Medicines two-step personalized immunotherapy treatment works. In the first step, the cancer patients own dendritic cells and tumor cells are used to generate a personalized vaccine that can kill the patient's own tumor. In step two, the patients T-cells trigger an anti-tumor immune response that kills cancer cells. The trial vaccine studys lead author, Lana Kandalaft, PharmD, PhD, MTR, Research Assistant Professor of Obstetrics and Gynecology and Director of Clinical Development and Operations in Penn Medicines Ovarian Cancer Research Center explained, This is the first time such a combination immunotherapy approach has been used for patients with ovarian cancer and we believe the results are leading us toward a completely new way to treat this disease. Patients with advanced ovarian cancer whose five-year survival rate is normally under 30% were treated with this personalized cancer vaccine are clearly benefiting from this immunotherapy combination.